Asia-Pacific leads in active clinical control studies
Active control trials are dominant in APAC due to diverse patient populations, lower trial costs and growing pharmaceutical markets.
Active control trials are dominant in APAC due to diverse patient populations, lower trial costs and growing pharmaceutical markets.